View
225
Download
0
Category
Preview:
DESCRIPTION
Figure 2. ab Need to replaced by the final figures highlow samples proteins cancercontrol ZW: we can cut the samples labels
Citation preview
Main Figures and Tables
Figure 1
Strategy (shall we make a strategy figure here??）
Figure 2.
a b
Need to replaced by the final figureshigh low
samples
prot
eins
cancercontrol
ZW: we can cut the samples labels
Figure 3.
Signaling pathway analysis of the differential proteins(pathway will be generated either by IPA or KEGG)
Total Adenocarcinoma Squamous Cell Carcinoma
n=375 n=186 n=189
T1 86 59 27T2 185 86 99T3 73 28 45T4 31 13 18
N0 214 108 106N1 56 19 37N2 96 52 44N3 4 3 1
Unknown 5 4 1
M0 363 176 187M1 12 10 2
R0 333 167 166R1 33 19 14R2 2 0 2
Unknown 7 0 7
1AB 139 82 572AB 98 33 653AB 117 57 604 11 10 1Unknown 10 4 6
Sex
Female 94 68 26Male 279 117 162Uknown 2 1 1
Age
Average 65 63 66Range 31-83 31-83 43-82
Clinicopathological parameters
T stage
Lymph node metastasis
Distant metastasis
Residual tumor
UICC Stage
Table 1.
Figure 4.
MELK in Adenocacinoma
Figure 5.
DAPK2 MELK
MELK in Squamouse cell carcinoma
Table 2. Correlation analysis
Supplementary Figures
Supplementary Figure S1 – PCA Analysis
proteins
A B C
controlcancer
controlcancer
PCA on samples without any filter
PCA on samples with p<0.05
PCA on proteins with p<0.05
EGFR
Squamouse cell carcinomaAdenocarcinoma
P = 0,006231P = 0,03599high expression
Ove
rall
Surv
ival
Pro
babi
lity
low expression
high expression
low expression
Overall Survival [months] Overall Survival [months]
Ove
rall
Surv
ival
Pro
babi
lity
0 50 100 150 200
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1
.0
0 50 100 150 200
Overall Survival [months]0.
0
0.2
0
.4
0.6
0
.8
1.0
Supplementary Figure S2
DAPK2
Adenocarcinoma & Squamouse cell carcinoma
P = 0,008825
low expression (n=45)
high expression (n=275)
Over
all S
urvi
val P
roba
bilit
y
0 50 100 150 200
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1
.0
Supplementary Figure S3
a.
DAPK2
P = 0,0198 P = 0,03282
low expression (n=33)
high expression (n=113)
Over
all S
urvi
val P
roba
bilit
y
low expression (n=12)
high expression (n=162)
0 50 100 150 200
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1
.0
0 50 100 150 200
Overall Survival [months]0.
0
0.2
0
.4
0.6
0
.8
1.0
Squamouse cell carcinomaAdenocarcinomab. c.
MELK
Adenocarcinoma & Squamouse cell carcinoma
P = 0,043
low expression (n=68)
high expression (n=291)
Over
all S
urvi
val P
roba
bilit
y
0 50 100 150 200
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1.0
Supplementary Figure S4
a.
MELK
low expression (n=40)
high expression (n=139) P = 0,017Over
all S
urvi
val P
roba
bilit
y
P = 0,69
low expression (n=28)
high expression (n=153)
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1
.0
0 50 100 150 200
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1
.0
0 50 100 150 200
Overall Survival [months]0.
0
0.2
0
.4
0.6
0
.8
1.0
Squamouse cell carcinomaAdenocarcinomab. c.
DDR1
P = 0,0485moderate expression (n=100)
high expression (n=54)
Over
all S
urvi
val P
roba
bilit
y
Overall Survival [months]
P = 0,7228low expression (n=29)
high expression (n=20)
low expression (n=157)
Overall Survival [months]0 50 100 150 200
Overall Survival [months]
0.0
0
.2
0.4
0
.6
0.8
1
.0
0 50 100 150 200
Overall Survival [months]0.
0
0.2
0
.4
0.6
0
.8
1.0
Squamouse cell carcinomaAdenocarcinomab. c.
Recommended